BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 169 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 169 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $257.20, for a total transaction of $43,466.80. Following the transaction, the insider directly owned 99,645 shares in the company, valued at $25,628,694. The trade was a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Up 1.4%

Shares of NASDAQ:ONC traded up $3.72 on Monday, reaching $268.20. The company had a trading volume of 351,440 shares, compared to its average volume of 258,341. The stock has a market capitalization of $29.43 billion, a P/E ratio of 60.00 and a beta of 0.49. The stock has a 50-day moving average price of $298.56 and a 200 day moving average price of $314.03. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $239.25 and a twelve month high of $385.22. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion for the quarter. On average, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ONC. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and lowered their target price for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Truist Financial reiterated a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a report on Thursday, May 7th. Wolfe Research began coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Finally, Barclays raised their price target on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $390.00.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in BeOne Medicines by 7.0% during the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock worth $120,354,000 after buying an additional 26,441 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in BeOne Medicines in the 1st quarter valued at approximately $3,475,000. EverSource Wealth Advisors LLC lifted its position in shares of BeOne Medicines by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after acquiring an additional 52 shares during the period. Royal Bank of Canada lifted its position in shares of BeOne Medicines by 3.5% in the 1st quarter. Royal Bank of Canada now owns 70,391 shares of the company’s stock worth $20,905,000 after acquiring an additional 2,399 shares during the period. Finally, Rokos Capital Management LLP bought a new stake in shares of BeOne Medicines in the 1st quarter worth approximately $4,256,000. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.